221 related articles for article (PubMed ID: 17968881)
1. Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype.
Jenkinson MD; Smith TS; Brodbelt AR; Joyce KA; Warnke PC; Walker C
J Magn Reson Imaging; 2007 Dec; 26(6):1405-12. PubMed ID: 17968881
[TBL] [Abstract][Full Text] [Related]
2. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features.
Jenkinson MD; du Plessis DG; Smith TS; Joyce KA; Warnke PC; Walker C
Brain; 2006 Jul; 129(Pt 7):1884-91. PubMed ID: 16670176
[TBL] [Abstract][Full Text] [Related]
3. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
4. MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes.
Jenkinson MD; Smith TS; Joyce K; Fildes D; du Plessis DG; Warnke PC; Walker C
Neurology; 2005 Jun; 64(12):2085-9. PubMed ID: 15985578
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Golanska E; Sikorska B; Liberski PP
Clin Neuropathol; 2006; 25(1):18-24. PubMed ID: 16465770
[TBL] [Abstract][Full Text] [Related]
6. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours.
Jenkinson MD; Smith TS; Joyce KA; Fildes D; Broome J; du Plessis DG; Haylock B; Husband DJ; Warnke PC; Walker C
Neuroradiology; 2006 Oct; 48(10):703-13. PubMed ID: 16937145
[TBL] [Abstract][Full Text] [Related]
7. Cellularity and apparent diffusion coefficient in oligodendroglial tumours characterized by genotype.
Jenkinson MD; du Plessis DG; Smith TS; Brodbelt AR; Joyce KA; Walker C
J Neurooncol; 2010 Feb; 96(3):385-92. PubMed ID: 19618117
[TBL] [Abstract][Full Text] [Related]
8. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms.
Zlatescu MC; TehraniYazdi A; Sasaki H; Megyesi JF; Betensky RA; Louis DN; Cairncross JG
Cancer Res; 2001 Sep; 61(18):6713-5. PubMed ID: 11559541
[TBL] [Abstract][Full Text] [Related]
9. Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19q deletion analysis in paraffin-embedded oligodendroglial tumor specimens.
Gelpi E; Ambros IM; Birner P; Luegmayr A; Drlicek M; Fischer I; Kleinert R; Maier H; Huemer M; Gatterbauer B; Anton J; Rössler K; Budka H; Ambros PF; Hainfellner JA
Mod Pathol; 2003 Jul; 16(7):708-15. PubMed ID: 12861068
[TBL] [Abstract][Full Text] [Related]
10. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas.
Watanabe T; Nakamura M; Kros JM; Burkhard C; Yonekawa Y; Kleihues P; Ohgaki H
Acta Neuropathol; 2002 Mar; 103(3):267-75. PubMed ID: 11907807
[TBL] [Abstract][Full Text] [Related]
11. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
van den Bent MJ; Looijenga LH; Langenberg K; Dinjens W; Graveland W; Uytdewilligen L; Sillevis Smitt PA; Jenkins RB; Kros JM
Cancer; 2003 Mar; 97(5):1276-84. PubMed ID: 12599236
[TBL] [Abstract][Full Text] [Related]
12. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.
Shukla B; Agarwal S; Suri V; Pathak P; Sharma MC; Gupta D; Sharma BS; Suri A; Halder A; Sarkar C
Neurol India; 2009; 57(5):559-66. PubMed ID: 19934553
[TBL] [Abstract][Full Text] [Related]
13. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
Weller M; Berger H; Hartmann C; Schramm J; Westphal M; Simon M; Goldbrunner R; Krex D; Steinbach JP; Ostertag CB; Loeffler M; Pietsch T; von Deimling A;
Clin Cancer Res; 2007 Dec; 13(23):6933-7. PubMed ID: 18056167
[TBL] [Abstract][Full Text] [Related]
14. Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis?
Fellah S; Caudal D; De Paula AM; Dory-Lautrec P; Figarella-Branger D; Chinot O; Metellus P; Cozzone PJ; Confort-Gouny S; Ghattas B; Callot V; Girard N
AJNR Am J Neuroradiol; 2013 Jul; 34(7):1326-33. PubMed ID: 23221948
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathology and clinical characteristics of oligodendroglial neoplasms.
Walker C; du Plessis DG; Joyce KA; Fildes D; Gee A; Haylock B; Husband D; Smith T; Broome J; Warnke PC
Ann Neurol; 2005 Jun; 57(6):855-65. PubMed ID: 15929038
[TBL] [Abstract][Full Text] [Related]
16. Correlations between molecular profile and tumor location in Chinese patients with oligodendroglial tumors.
Huang L; Jiang T; Yuan F; Li GL; Liu EZ; Wang ZC
Clin Neurol Neurosurg; 2008 Dec; 110(10):1020-4. PubMed ID: 18845382
[TBL] [Abstract][Full Text] [Related]
17. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
[TBL] [Abstract][Full Text] [Related]
18. Can morphology predict 1p/19q loss in oligodendroglial tumours?
Scheie D; Cvancarova M; Mørk S; Skullerud K; Andresen PA; Benestad I; Helseth E; Meling T; Beiske K
Histopathology; 2008 Nov; 53(5):578-87. PubMed ID: 18983467
[TBL] [Abstract][Full Text] [Related]
19. MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status.
Sherman JH; Prevedello DM; Shah L; Raghavan P; Pouratian N; Starke RM; Lopes MB; Shaffrey ME; Schiff D
Acta Neurochir (Wien); 2010 Nov; 152(11):1827-34. PubMed ID: 20711790
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
